Analyst Rating Update on Inovio Pharmaceuticals (INO)

Inovio Pharmaceuticals (NASDAQ:INO) : 5 brokerage houses believe that Inovio Pharmaceuticals (NASDAQ:INO) is a Strong Buy at current levels. Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 5 Wall Street Analysts endorse the stock as a Strong Buy with a rating of 1.

Inovio Pharmaceuticals (NASDAQ:INO) stock is expected to deviate a maximum of $7.23 from the average target price of $18.6 for the short term period. 5 Street Experts have initiated coverage on the stock with the most promising target being $31 and the most muted being $13.

For the current week, the company shares have a recommendation consensus of Buy.

Inovio Pharmaceuticals (NASDAQ:INO): stock turned positive on Tuesday. Though the stock opened at $8.45, the bulls momentum made the stock top out at $9.267 level for the day. The stock recorded a low of $8.45 and closed the trading day at $9.21, in the green by 11.10%. The total traded volume for the day was 2,190,374. The stock had closed at $8.29 in the previous days trading.

In an insider trading activity, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director of Inovio Pharmaceuticals, Inc., Benito Simon X had sold 6,250 shares worth of $64,813 in a transaction dated May 18, 2016. In this transaction, 6,250 shares were sold at $10.37 per share.

Inovio Pharmaceuticals, Inc. (Inovio) is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. As of December 31, 2014, Inovio had completed clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), HIV, influenza and Ebola. With its immunotherapy platform consisting of SynCon products, as well as its CELLECTRA electroporation delivery technology, Inovio has developed a pipeline of pre-clinical and clinical stage products that have generated in vivo (in the body) immune responses. Inovios immunotherapies are delivered into cells of the body into a small local area of tissue using its electroporation (EP) DNA delivery technology.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.